Immunogenicity and short term reactogencity of cellular DTP vaccine in Iranian children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138902072471N2

Enrollment

600

Registered

2010-06-14

Start date

2005-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DTP. Need for immunization against diphtheria-tetanus-pertussis, combined [DTP]

Interventions

Intervention 1: Injecting vaccine that is approved by WHO (control group). Intervention 2: Injecting Iranian Vaccine (case group).

Treatment - Drugs

Injecting vaccine that is approved by WHO (control group)

Injecting Iranian Vaccine (case group)

Eligibility

Sex/Gender

All

Age

No minimum to 6 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Healthy children Exclusion criteria: Incomplete vaccination card, immunodeficiency disease, severe asthma and allergy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Antibody response against Diphtheria, Tetanus and Pertussis. Timepoint: one month. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Comparison DTP vaccine reactogencity. Timepoint: Immediate after vaccine. Method of measurement: Checking by parents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fazel Shokri

Avicenna Research institute

fazshok@yahoo.com+98 21 2243 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026